We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Gene Found for Common Form of Epilepsy

By LabMedica International staff writers
Posted on 18 Apr 2013
A gene mutation linked to the most common form of epilepsy has been found that could in the future lead to a genetic test for the condition.

The use of exome sequencing detected the gene for autosomal dominant familial focal epilepsy with variable foci (FFEVF) which is notable because family members have seizures originating from different cortical regions. More...


A team of scientists working with those at University of South Australia (Adelaide, SA, Australia) studied about 90 families where two members had epilepsy. The exomes of individuals were independently sequenced both in Australia and in The Netherlands. The coding sequences were enriched using the SureSelect Human All Exon 50Mb kit (Agilent Technologies; Santa Clara, CA, USA). After sequence capture and amplification, fragments were sequenced using a SOLiD v4 instrument (Applied Biosystems; Mulgrave, VIC, Australia).

The results showed that a gene called DEP domain-containing 5 (DEPDC5) causes focal epilepsy in about 12% of families in which only two people have focal epilepsy. This high frequency establishes DEPDC5 mutations as a common cause of familial focal epilepsies. As well as opening new opportunities for diagnosing epilepsy, the scientists believe their discovery will also lead to better targeted treatments.

The identification of DEPDC5 as the gene underlying FFEVF substantially advances understanding of the pathogenesis of epilepsy by implicating another new gene pathway. Apart from enabling the diagnosis of FFEVF through molecular testing, these findings also enable strategies to be devised to improve prognosis through tailored treatment targeting DEPDC5.

Ingrid E. Scheffer, MD, professor and pediatric neurologist, of the Florey Neuroscience Institute (Melbourne, VIC, Australia) said, "This discovery is paradigm shifting, if you have focal epilepsy and there is no cause known, then this gene should be tested to look for a mutation." The study was published on March 31, 2013, in the journal Nature Genetics.

Related Links:
University of South Australia
Agilent Technologies
Applied Biosystems



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.